Jul 16, 2026 06:47AM

Jun 15, 2026 07:02AM

May 5, 2026 04:20AM

May 4, 2026 01:15PM

Apr 1, 2026 05:41PM

Apr 1, 2026 12:10PM

Feb 24, 2026 05:40AM Axsome Therapeutics (AXSM) PT Raised to $220 at Guggenheim

Feb 23, 2026 12:32PM

Feb 2, 2026 09:00AM

Jan 20, 2026 06:39AM

Jan 13, 2026 04:52AM

Jan 2, 2026 08:53AM

Dec 31, 2025 01:54PM

Dec 31, 2025 01:19PM Axsome Therapeutics (AXSM) PT Raised to $217 at Mizuho

Dec 31, 2025 12:42PM

Dec 31, 2025 08:25AM

Dec 31, 2025 08:24AM

Dec 31, 2025 06:55AM

Nov 6, 2025 07:01AM

Jul 22, 2025 07:28AM

Jul 22, 2025 06:38AM Mizuho Reiterates Outperform Rating on Axsome Therapeutics (AXSM)

Jul 18, 2025 09:58AM

Jun 10, 2025 09:24AM

Jun 10, 2025 06:39AM

Jun 9, 2025 11:54AM

Jun 9, 2025 07:02AM

Apr 7, 2025 02:31AM

Apr 4, 2025 07:00AM Axsome Therapeutics (AXSM) Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05

Jan 21, 2025 06:41AM

Jan 13, 2025 12:50PM

Nov 26, 2024 07:00AM

Sep 16, 2024 08:43AM

Mar 28, 2024 06:29AM

Mar 26, 2024 07:23AM

Mar 25, 2024 06:31AM Axsome Therapeutics (AXSM) Reports AXS-12 Met Primary Endpoint in the SYMPHONY Phase 3 Trial

Mar 19, 2024 03:34AM

Jan 4, 2024 07:04AM

Nov 1, 2022 05:34AM

Apr 19, 2022 09:24AM

Jun 15, 2021 07:01AM

Sep 21, 2020 07:04AM

Aug 5, 2020 07:18AM Axsome Therapeutics (AXSM) Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy

Jan 13, 2020 06:05AM

Dec 17, 2019 09:19AM

Dec 3, 2019 09:16AM

Dec 3, 2019 06:05AM

Oct 21, 2019 07:02AM

Oct 2, 2019 08:47AM

Jan 30, 2019 07:00AM Axsome Therapeutics (AXSM) Commences Phase 2 Trial of AXS-12 in Narcolepsy

Dec 27, 2018 07:01AM

67,309 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All